MedTrace Logo

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

NCT06669143 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-11-01

No results posted yet for this study

Summary

This single-arm, prospective clinical study will evaluate the efficacy and safety of Zanubrutinib-based maintenance therapy for post-remission in newly diagnosed DLBCL who are intolerant to first-line intensive chemotherapy.

Conditions

Interventions

DRUG

Zanubrutinib

160 mg bid, po, day 1-21, a maximum of 2 years.

DRUG

Lenalidomide

25 mg qd, po, day 1-10, a maximum of 2 years.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2026-11-30
Completion
2027-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06669143 on ClinicalTrials.gov